Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use

被引：9

作者：

Sotomi, Yohei ^{[1
]}

Suwannasom, Pannipa ^{[1
,2
,3
]}

Tenekecioglu, Erhan ^{[2
]}

Tateishi, Hiroki ^{[2
]}

Abdelghani, Mohammad ^{[1
]}

Serruys, Patrick W. ^{[4
]}

Onuma, Yoshinobu ^{[2
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands

[2] Erasmus MC, ThoraxCtr, Rotterdam, Netherlands

[3] Chiang Mai Univ, Fac Med, Northern Region Heart Ctr, Chiang Mai, Thailand

[4] Imperial Coll London, NHLI, Int Ctr Circulatory Hlth, London, England

来源：

EXPERT REVIEW OF CARDIOVASCULAR THERAPY | 2015年 / 13卷 / 10期

关键词：

bioresorbable vascular scaffold; drug-eluting stent; intravascular imaging; percutaneous coronary intervention; randomized controlled trial;

D O I：

10.1586/14779072.2015.1089172

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use.

引用

页码：1127 / 1145

页数：19

共 97 条

[91] Gori T., Schulz E., Hink U., Et al., Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes, EuroIntervention, 9, 9, pp. 1036-1041, (2014)
[92] Cortese B., Ielasi A., Romagnoli E., Et al., Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions, Am J Cardiol, (2015)
[93] Wiebe J., Mollmann H., Most A., Et al., Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold, Clin Res Cardiol, 103, 2, pp. 141-148, (2014)
[94] Diletti R., Karanasos A., Muramatsu T., Et al., Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study, Eur Heart J, 35, 12, pp. 777-786, (2014)
[95] Yew K.L., Novel use of absorb bioresorbable vascular scaffold and STENTYS self-apposing coronary stent for complex saphenous vein grafts intervention, Int J Cardiol, 177, 3, pp. e184-e185, (2014)
[96] Ielasi A., Latib A., Naganuma T., Et al., Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis, Int J Cardiol, 173, 3, pp. 513-514, (2014)
[97] Kajiya T., Liang M., Sharma R.K., Et al., Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI), EuroIntervention, 9, 4, pp. 501-504, (2013)

← 1 2 3 4 5 6 7 8 9 10 →